Reporter brief
Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans: A Phase 2, Single-Center, 20-week, Open-Label, Randomized Controlled Trial.
What happened
Trial registry update: COMPLETED. Results are posted in the registry; assessment pending.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- The abstract does not report what the study actually found, making it impossible to assess whether senolytics achieved the stated objectives or produced clinically meaningful changes in bone health
- Open-label design means both participants and staff knew treatment assignment, allowing bias in outcome assessment
- Clinical bone health improvements (fracture risk, bone density, strength) were not stated as outcomes measured
Study design and sample
Rct; Human.
Elderly women
- Design
- Rct
- Sample
- —
- Journal
- Not clearly reported; author named as Sundeep Khosla, M.D.
- Published
- Jul 22, 2024
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.